Endah Rahmawati, Wei‐Chung V. Yang, Yen‐Ping Lei, Pawan K. Maurya, Huei‐Wen Chen, Chii‐Ruey Tzeng
Abstract
Introduction: Many cell migration‐related molecules are associated with endometri‐osis. Tensin 1 (TNS1), which has been implicated in cell migration, may play a role inendometriosis. The study goal was to evaluate the TNS1 expression in endometrialtissue and serum from women with endometriosis treated with gonadotropin‐releas‐ing hormone agonist (GnRHa).
Material and methods: Tissue and serum samples were collected from women withendometriosis who were treated (n = 29) with GnRHa or untreated (n = 30). TNS1mRNA was examined using quantitative PCR. TNS1 protein levels in tissue and serumsamples were investigated using Western blot, immunohistochemistry and ELISA.Eleven women with endometriosis participated in a follow‐up investigation of serumTNS1 before and after GnRHa treatment.
Results: TNS1 mRNA (P = 0.006) and protein (P = 0.001) were significantly down‐regulated in endometriotic tissue from women with endometriosis who receivedGnRHa. Immunolocalization of TNS1 showed strong expression in the epithelial andstromal cells of endometriotic tissue from women untreated with GnRHa, whereasendometriotic tissue from GnRHa‐treated women showed low TNS1 expression.Follow‐up monitoring of serum TNS1 concentration in 11 women showed an averagedecrease in concentration of 53%, from 294.9 ± 66.69 to 140.3 ± 55.21 pg/mL, fol‐lowing GnRHa treatment (P = 0.003).
Conclusions: GnRHa induces downregulation of TNS1 in tissue and serum in womenwith endometriosis. These results emphasize the importance TNS1 as a potentialtherapeutic molecular target for the treatment of endometriosis with GnRHa.
Material and methods: Tissue and serum samples were collected from women withendometriosis who were treated (n = 29) with GnRHa or untreated (n = 30). TNS1mRNA was examined using quantitative PCR. TNS1 protein levels in tissue and serumsamples were investigated using Western blot, immunohistochemistry and ELISA.Eleven women with endometriosis participated in a follow‐up investigation of serumTNS1 before and after GnRHa treatment.
Results: TNS1 mRNA (P = 0.006) and protein (P = 0.001) were significantly down‐regulated in endometriotic tissue from women with endometriosis who receivedGnRHa. Immunolocalization of TNS1 showed strong expression in the epithelial andstromal cells of endometriotic tissue from women untreated with GnRHa, whereasendometriotic tissue from GnRHa‐treated women showed low TNS1 expression.Follow‐up monitoring of serum TNS1 concentration in 11 women showed an averagedecrease in concentration of 53%, from 294.9 ± 66.69 to 140.3 ± 55.21 pg/mL, fol‐lowing GnRHa treatment (P = 0.003).
Conclusions: GnRHa induces downregulation of TNS1 in tissue and serum in womenwith endometriosis. These results emphasize the importance TNS1 as a potentialtherapeutic molecular target for the treatment of endometriosis with GnRHa.
K E Y W O R D Sendometriosis, gonadotropin‐releasing hormone agonist, tensin 1
Acta Obstet Gynecol Scand. 2019 Feb;98(2):222-231. doi: 10.1111/aogs.13481. Epub 2018 Nov 11. PMID: 30312486.
